Literature DB >> 28591277

Evaluation of nicotinamide as an anti-inflammatory and anti-angiogenic agent in uveal melanoma cell lines.

Evangelina Esposito1, Sultan Aldrees1,2, Christina Mastromonaco1, Pablo Zoroquiain1, Natalia Vila1, Patrick T Logan1, Shriya Hari1, Miguel N Burnier1.   

Abstract

PURPOSE: : To investigate the effect of nicotinamide on the secretion of pro-an giogenic and pro-inflammatory cytokines in uveal melanoma cell lines.
METHODS: : Two human uveal melanoma cell lines (92.1 and OCM-1) were treated with nicotinamide (10 mmol/L) or control media for 48 hours in culture. The su perna tant from each culture was used in sandwich enzyme-linked immuno sorbent assay-based angiogenesis and inflammation arrays to evaluate the effects of exogenously administered nicotinamide on the secretion of a total of 20 pro-an gio genic and pro-inflammatory proteins.
RESULTS: : Seven pro-angiogenic cytokines were detected under control conditions for both uveal melanoma cell lines. Treatment with nicotinamide resulted in a significant decrease in secretion of the following pro-angiogenic cytokines: angiogenin, angiopoietin-2, epidermal growth factor, and vascular epithelial growth factor-A in the 92.1 cells; basic fibroblast growth factor in the OCM-1 cells; and placenta growth factor in both cell lines. Among the pro-inflammatory proteins, monocyte chemotactic protein-1 and interleukin-8 were expressed in both untreated cell lines and both were significantly reduced when treated with nicotinamide.
CONCLUSIONS: : Results from this in vitro model suggest that nicotinamide may have anti-inflammatory and anti-angiogenic properties, which may open the possibility of using it as a chemopreventive agent for uveal melanoma; however, further studies including animal models are warranted.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28591277     DOI: 10.5935/0004-2749.20170019

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  3 in total

Review 1.  Oral nicotinamide for non-melanoma skin cancers: A review.

Authors:  Samantha Vicki Hunt; Aaron Jamison; Raman Malhotra
Journal:  Eye (Lond)       Date:  2022-03-28       Impact factor: 4.456

2.  Overexpression of angiogenic factors and matrix metalloproteinases in the saliva of oral squamous cell carcinoma patients: potential non-invasive diagnostic and therapeutic biomarkers.

Authors:  Meijuan Cai; Zhichao Zheng; Zhibao Bai; Kexiong Ouyang; Qiuyu Wu; Shaofen Xu; Lihuan Huang; Yingtong Jiang; Lijing Wang; Jie Gao; Janak L Pathak; Lihong Wu
Journal:  BMC Cancer       Date:  2022-05-11       Impact factor: 4.638

3.  An unusual nicotinamide derivative, 4-pyridone-3-carboxamide ribonucleoside (4PYR), is a novel endothelial toxin and oncometabolite.

Authors:  Paulina Mierzejewska; Michal Kunc; Magdalena Agnieszka Zabielska-Kaczorowska; Barbara Kutryb-Zajac; Iwona Pelikant-Malecka; Alicja Braczko; Patrycja Jablonska; Pawel Romaszko; Patrycja Koszalka; Jolanta Szade; Ryszard Tomasz Smolenski; Ewa Maria Slominska
Journal:  Exp Mol Med       Date:  2021-09-27       Impact factor: 12.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.